205 - Why Less Than 20% of Companies Have Started Quality 4.0

205 - Why Less Than 20% of Companies Have Started Quality 4.0

Nearly two-thirds of companies believe Quality 4.0 will transform their operations in the next five years yet fewer than 20% have started, and most haven’t even reached the planning stage. In this conversation, Larry Mager breaks down what Quality 4.0 really is, why life sciences lag other industries, and how to move from compliance-only thinking to a business-driving quality strategy. We cover digital twins, data continuity, culture change, and Larry’s Quantum Quality Management (QQM) framework as a practical roadmap.Timestamps00:00 Introduction to Quality 4.000:20 Defining Quality 4.001:39 The Role of Quality Professionals02:50 Industry Examples & Cultural Differences04:04 Implementing Quality 4.0 (people, process, tech)08:49 The Digital Twin Concept (why legacy EQMS falls short)13:34 The Importance of a Roadmap 30:28 Quantum Quality Management (5-phase framework)35:05 Final Thoughts & Contact InformationLarry Mager is the Founder and Principal at MGMT-CTRL, where he specializes in applying strategic quality management that goes beyond mere compliance. With three decades of experience in the medical device industry, Larry has held leadership roles spanning quality systems, operations management, CAPA, supplier control, risk management, lean manufacturing, and continuous improvement. He is also the architect of the Quantum Quality Management (QQM) framework, a phased methodology that marries people, process, and technology to help organizations adopt Quality 4.0, drive operational excellence, and use quality as a strategic business advantage.Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(245)

224 - ICH Q2 Explained: What Analytical Validation Really Requires

224 - ICH Q2 Explained: What Analytical Validation Really Requires

In this episode of Let’s Combinate, host Subhi Saadeh breaks down the ICH Q2 guideline with a practical focus on analytical procedure validation. The discussion covers key definitions, core validation...

28 Tammi 10min

223 - What’s Changing in ICH Q1 and What Isn’t: Understanding Stability Expectations

223 - What’s Changing in ICH Q1 and What Isn’t: Understanding Stability Expectations

In this episode of Let’s Combinate: Drugs and Devices, host Subhi Saadeh breaks down the 2025 draft update to the ICH Q1 guideline and explains what has actually changed and what has stayed the same.I...

21 Tammi 9min

222 - How ICH Guidelines Are Organized: Understanding the Q, S, E, and M Series

222 - How ICH Guidelines Are Organized: Understanding the Q, S, E, and M Series

In this episode of Let’s Combinate: Drugs + Devices, host Subhi Saadeh continues the Combinating with ICH series by breaking down how the International Council for Harmonisation (ICH) guidelines are o...

14 Tammi 12min

221 - What Is ICH and Why It Matters

221 - What Is ICH and Why It Matters

In this episode of Let’s Combinate: Drugs + Devices, Subhi Saadeh kicks off a new series focused on the International Council for Harmonisation (ICH) and its impact on drug and drug–device combination...

7 Tammi 14min

220 - Managing Oneself, Reflections and a New Series on ICH

220 - Managing Oneself, Reflections and a New Series on ICH

🚀 Stay ahead in combination products, pharma, and medical devices 👉 https://www.letscombinate.com🎙️ Listen to more expert discussions on regulations, drug delivery, and quality 👉 https://www.letsc...

31 Joulu 20258min

219 - FDA PreCheck and the Future of Inspections: PAI to Pre-Readiness

219 - FDA PreCheck and the Future of Inspections: PAI to Pre-Readiness

In this episode of Let’s Combinate: Drugs + Devices, host Subhi Saadeh is joined by Ben Locwin to break down what’s changing in FDA pre-approval and pre-license inspections—and why the “inspection sid...

24 Joulu 202525min

218 - ICH Q13: Continuous Manufacturing EXPLAINED (Batch vs. Continuous)

218 - ICH Q13: Continuous Manufacturing EXPLAINED (Batch vs. Continuous)

In this short episode of Let’s Combinate: Drugs + Devices, Subhi Saadeh breaks down ICH Q13 and what “continuous manufacturing” actually means. He compares batch vs. continuous, explains how a batch s...

17 Joulu 20259min

217 - 5 Fixable Problems Holding Back Drug–Device Programs

217 - 5 Fixable Problems Holding Back Drug–Device Programs

In this episode of Let's Combinate: Drugs + Devices, host Subhi Saadeh addresses five significant quality issues in the combination product space. This episode provides practical insights and strategi...

10 Joulu 202517min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
rss-poliisin-mieli
tiedekulma-podcast
rss-tiedetta-vai-tarinaa
utelias-mieli
docemilia
sotataidon-ytimessa
filocast-filosofian-perusteet
menologeja-tutkimusmatka-vaihdevuosiin
rss-bios-podcast
rss-ranskaa-raakana
rss-duodecim-lehti
rss-duokkari-ekstra
rss-astetta-parempi-elama-podcast
rss-metsantuntijat-podcast
rss-ilmasto-kriisissa
rss-ylistys-elaimille
rss-sosiopodi